Figure 3From: Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trialPercentages of patients in remission, with low disease activity and with good or moderate European League Against Rheumatism response criteria [30]. DA, Disease activity; EULAR, European League Against Rheumatism; TNFi, Tumour necrosis factor inhibitor.Back to article page